ACE inhibitor

Angiotensin-converting enzyme (ACE) inhibitors are a class of medication used primarily for the treatment of hypertension, heart failure, and the prevention of cardiovascular and renal complications. They work by inhibiting the angiotensin-converting enzyme, a key component of the renin-angiotensin-aldosterone system (RAAS), thereby preventing the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. This mechanism results in the relaxation of blood vessels, a decrease in blood pressure, and a reduction in the workload on the heart.

Mechanism of Action

The primary mechanism of ACE inhibitors involves the blockade of the angiotensin-converting enzyme, which is responsible for converting the inactive decapeptide angiotensin I into the active octapeptide angiotensin II. Angiotensin II is a powerful vasoconstrictor that also stimulates the release of aldosterone from the adrenal cortex, leading to sodium and water retention. By inhibiting this enzyme, ACE inhibitors reduce angiotensin II levels, resulting in vasodilation, decreased systemic vascular resistance, and reduced aldosterone secretion, which promotes sodium and water excretion.

Additionally, ACE is identical to kininase II, the enzyme responsible for the degradation of bradykinin, a potent vasodilator. Inhibition of ACE leads to increased levels of bradykinin, which further contributes to vasodilation through the release of nitric oxide and prostacyclin. This dual mechanism—decreasing vasoconstrictors and increasing vasodilators—underpins the cardiovascular and renal benefits of the drug class.

Medical Uses

ACE inhibitors are widely prescribed for a variety of cardiovascular and renal conditions. Their primary indications include:

• Hypertension: They are considered first-line agents for the management of high blood pressure, either as monotherapy or in combination with other antihypertensive drugs.
• Heart Failure: By reducing afterload and preload, ACE inhibitors improve cardiac output, reduce symptoms, and significantly decrease mortality and hospitalization rates in patients with heart failure with reduced ejection fraction.
• Post-Myocardial Infarction: They are used to prevent ventricular remodeling and improve survival in patients who have recently suffered a myocardial infarction, particularly those with left ventricular dysfunction.
• Diabetic Nephropathy and Chronic Kidney Disease: ACE inhibitors provide renoprotective effects by reducing intraglomerular pressure and decreasing proteinuria, slowing the progression of kidney disease in patients with diabetes and other chronic renal conditions.

Common Medications

ACE inhibitors are typically recognized by their generic names, which end in the suffix "-pril". Some of the most commonly prescribed medications in this class include:

• Captopril (the first ACE inhibitor developed)
• Enalapril
• Lisinopril
• Ramipril
• Perindopril
• Quinapril
• Benazepril
• Fosinopril
• Trandolapril

These drugs vary in their pharmacokinetic properties, such as bioavailability, half-life, and routes of elimination (renal vs. hepatic), allowing clinicians to tailor therapy to individual patient needs.

Adverse Effects

While generally well-tolerated, ACE inhibitors are associated with several notable adverse effects:

• Dry Cough: A persistent, dry cough is the most common side effect, occurring in up to 20% of patients. It is believed to be caused by the accumulation of bradykinin and substance P in the respiratory tract.
• Angioedema: A rare but potentially life-threatening swelling of the deeper layers of the skin, often affecting the face, lips, tongue, and airway. This is also linked to elevated bradykinin levels.
• Hyperkalemia: Reduced aldosterone secretion can lead to potassium retention, increasing the risk of elevated serum potassium levels, particularly in patients with renal impairment or those taking potassium-sparing diuretics.
• Hypotension: First-dose hypotension can occur, especially in patients who are volume-depleted or already on multiple antihypertensive medications.
• Acute Kidney Injury: In susceptible individuals, such as those with bilateral renal artery stenosis, ACE inhibitors can cause a significant drop in glomerular filtration rate, leading to acute renal failure.
• Teratogenicity: ACE inhibitors are contraindicated in pregnancy due to the risk of fetal renal dysgenesis, oligohydramnios, and skull hypoplasia.

Contraindications

The use of ACE inhibitors is strictly contraindicated in patients with a history of angioedema associated with previous ACE inhibitor therapy. They are also contraindicated in pregnant women due to known teratogenic effects. Furthermore, they should be avoided in patients with bilateral renal artery stenosis (or unilateral stenosis in a solitary kidney) due to the high risk of precipitating acute renal failure. Caution is also advised when co-administering ACE inhibitors with direct renin inhibitors like aliskiren in patients with diabetes or renal impairment.

History and Development

The development of ACE inhibitors is a landmark achievement in rational drug design. The origins of this drug class trace back to the 1960s when researchers discovered that the venom of the Brazilian pit viper (Bothrops jararaca) contained a peptide that potentiated the effects of bradykinin and inhibited the conversion of angiotensin I to angiotensin II.

Building on this discovery, scientists at the Squibb Institute for Medical Research, notably David Cushman and Miguel Ondetti, isolated the active component and used its structure to design the first orally active ACE inhibitor, captopril, which was approved by the FDA in 1981. Captopril paved the way for the development of subsequent, longer-acting ACE inhibitors like enalapril and lisinopril, which lack the sulfhydryl group of captopril and have improved side-effect profiles. The introduction of ACE inhibitors revolutionized the management of cardiovascular diseases and remains a cornerstone of modern pharmacotherapy.